Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 16.0

Eligibility Criteria:
Inclusion Criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Male or female, age 18 years or older at the time of signing inform consent - Body mass index (BMI) equal or above 30.0 kg/m\^2 at the screening visit - At least one unsuccessful weight loss attempt per investigator judgement Exclusion Criteria: - A HbA1c (glycosylated haemoglobin) equal to or above 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus - Treatment with glucose lowering agent(s) within 90 days before screening - Screening calcitonin equal to or above 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 - History of pancreatitis (acute or chronic) - Obesity induced by endocrine disorders (e.g. Cushing Syndrome) - Treatment with any medication within 90 days before screening that based on investigator's judgement may cause significant weight change - Previous surgical treatment for obesity (liposuction and/or abdominoplasty performed 1 year before screening is allowed) - History of major depressive disorder within 2 years before randomisation - Any lifetime history of a suicidal attempt - Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sema 0.05 mg (Type: EXPERIMENTAL): Dose 0.05 mg
- Sema 0.1 mg (Type: EXPERIMENTAL): Dose 0.05 or 0.1 mg with dose escalation every fourth week
- Sema 0.2 mg (Type: EXPERIMENTAL): Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
- Sema 0.3 mg (Type: EXPERIMENTAL): Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
- Sema 0.4 mg (Type: EXPERIMENTAL): Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
- Sema 0.3 mg (fast dose escalation) (Type: EXPERIMENTAL): Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
- Sema 0.4 mg (fast dose escalation) (Type: EXPERIMENTAL): Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
- Lira 3.0 mg (Type: ACTIVE_COMPARATOR): Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
- Placebo Sema 0.05 mg (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Sema 0.05 mg
- Placebo Sema 0.1 mg (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Sema 0.1 mg
- Placebo Sema 0.2 mg (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Sema 0.2 mg
- Placebo Sema 0.3 mg (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Sema 0.3 mg
- Placebo Sema 0.4 mg (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Sema 0.4 mg
- Placebo Sema 0.3 mg (fast dose escalation) (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
- Placebo Sema 0.4 mg (fast dose escalation) (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
- Placebo Lira 3.0 mg (Type: PLACEBO_COMPARATOR): Placebo arm matching active arm Lira 3.0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).